Please assess the completion status of the following clinical trial:

Trial Title: Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is male or female outpatient between 18-64 years old.~* The subject meets DSM-IV criteria for Generalized Anxiety Disorder or Obsessive Compulsive Disorder as determined by the MINI.~* Sexually active female patients of childbearing potential must be practicing at least one or more the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception or abstinence. Female patients of childbearing potential must have a negative pregnancy test prior to receiving study drug.~* Written informed consent must be obtained from the subject prior to study participation.~* The subject is in good medical health or with chronic medical conditions which are currently stable.~* No current abuse of alcohol or other substance.~* The subject has a total score of 20 or more on the HARS or YBOCS at screening (for GAD and OCD, respectively)~* The subject has a Clinical Global Impression (CGI) Severity score of 4 or more at screening.~Exclusion Criteria:~* The subject meets DSM-IV criteria for an Axis I diagnosis (other than GAD or OCD) as the primary diagnosis (i.e., schizophrenia, mood disorder, psychosis, anorexia nervosa) as determined by the MINI.~* The subject is clinically judged by the investigator to be at risk for suicide or is acutely suicidal as objectively measured by the MINI and MSE.~* The subject is clinically judged by the investigator to be at risk for homicide or is acutely homicidal as objectively measured by the MINI and MSE.~* The subject has a psychiatric condition that would require inpatient, or partial psychiatric hospitalization.~* Seizure disorders.~* Significant history of medical disease (i.e. cardiovascular, hepatic (e.g. cirrhosis, hepatitis B or C) renal, gynecological, musculoskeletal, neurological, gastrointestinal, metabolic, hematological, endocrine, cancer with a metastatic potential or progressive neurological disorders) which could impair reliable participation in the trial or necessitate the use of medication not allowed by this protocol.~* The subject is pregnant, planning to become pregnant, or nursing. If a subject becomes pregnant, she will be discontinued immediately and followed appropriately.~* Concomitant therapy with another investigational drug, or participation in an investigational drug study within one month prior to entering this study.~* Current psychotherapeutic treatment except for treatment with Specific Reuptake Inhibitor (SSRIs) medications which include: Fluoxetine (Prozac), Paroxetine (Paxil), Sertraline (Zoloft), Luvox (Fluvoxamine), and Citalopram. Potential subjects may remain on one of the SSRI medications provided that he or she has been on a stable dose for at least 4 weeks prior to entering this study; this dose remains stable throughout the remainder of this study; and it can be determined that this medication is not exacerbating the anxiety symptoms.~* History of poor compliance or in the Investigator's judgment patients any subject whose treatment as an outpatient would be clinically contraindicated~* The subject has attempted suicide one or more times within the past twelve months~* The subject has a Structured Hamilton Depression Rating Scale (SIGH-D) score above 38 which suggests a moderate to severe clinical level of depressive symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- OCD group (Type: ACTIVE_COMPARATOR): OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
- GAD group (Type: ACTIVE_COMPARATOR): GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).